メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
中井 剛
臨床薬剤科
h-index
326
被引用数
8
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2011
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(17)
類似のプロファイル
(6)
フィンガープリント
Tsuyoshi Nakaiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Neuroscience
Cognitive Disorders
100%
Astrocyte
100%
Hippocampus
67%
Alzheimer's Disease
64%
Stromelysin
52%
Synaptic Plasticity
50%
Nerve Cell Differentiation
50%
Brain-Derived Neurotrophic Factor
50%
Dementia Praecox
50%
Interferon
50%
Hyperphosphorylation
50%
Exon
50%
NMDA Receptor
50%
Nobiletin
50%
Bioflavonoid
50%
Transmembrane Protein
50%
Akt Signaling
50%
Follistatin
50%
S-Allyl Cysteine
50%
Garlic Extract
50%
Dopaminergic
50%
Reelin
50%
Polycytidylic Acid
40%
Interneuron
33%
Learning Disabilities
26%
Neuronal Migration
25%
Memory Disorder
24%
Parvalbumin
16%
Nucleus Accumbens
16%
Dopaminergic Neuron
16%
Gamma-Aminobutyric Acid
16%
Oxidative Stress
14%
Eicosanoid Receptor
13%
Neurodegenerative Disorder
12%
Neuronal Plasticity
10%
Cell Migration
10%
Long-Term Potentiation
10%
Actin Cytoskeleton
10%
Kinase
10%
Actin Binding Protein
10%
Protein Serine Threonine Kinase
10%
Long-Term Memory
10%
Serine
10%
Alanine
10%
Pervasive Developmental Disorder
8%
Mood Disorder
8%
GABAA Receptor
8%
Receptor Subunit
8%
Impulsivity
8%
Glutathione Peroxidase
7%
Pharmacology, Toxicology and Pharmaceutical Science
Cognitive Defect
100%
Thrombocytopenia
100%
Alzheimer's Disease
64%
Mouse
55%
Gemcitabine
50%
Randomized Controlled Trial
50%
Cisplatin
50%
Biological Marker
50%
Senescence Accelerated Mouse
50%
Combination Therapy
50%
Bioflavonoid
50%
Nobiletin
50%
Malignant Neoplasm
50%
Garlic Extract
50%
S-Allyl Cysteine
50%
Colorectal Cancer
50%
Capecitabine Plus Oxaliplatin
50%
Disproportionality Analysis
50%
Immune Checkpoint Inhibitor
50%
Pharmacovigilance
50%
Pharmacokinetics
50%
Tranexamic Acid
50%
Hyperthyroidism
37%
Learning Disorder
21%
Oxaliplatin
20%
Cardiovascular Disease
16%
Mouse Model
16%
Comorbidity
16%
Fibrosis
15%
Memory Disorder
14%
Transgenic Mouse
12%
Chemotherapy
12%
Aminotransferase
10%
Glutathione Peroxidase
7%
N Methyl Dextro Aspartic Acid Receptor Blocking Agent
7%
Citrus
7%
Flavone
7%
Natural Product
7%
Degenerative Disease
7%
Manganese Superoxide Dismutase
7%
Amyloid Precursor Protein
7%
Amnesia
7%
Adverse Event
6%
Tree
6%
Cohort Study
6%
Ipilimumab
6%
Tremelimumab
6%
Nivolumab
6%
Pembrolizumab
6%
Durvalumab
6%
Keyphrases
Matrix metalloproteinase-3 (MMP-3)
50%
Platinum(IV)
50%
Follistatin-like 1
50%
Oxidative Load
50%
Innate Immune Response
50%
Cognitive Impairment
50%
Senescence-accelerated Mouse
50%
Neurodevelopmental Impairment
50%
Citrus Flavonoids
50%
Nobiletin
50%
Tau Hyperphosphorylation
50%
Astrocyte-conditioned Medium
50%
Astrocyte Activation
50%
Garlic Extract
50%
S-allyl Cysteine
50%
Multicenter Retrospective Study
50%
Catheter-related Bloodstream Infection (CRBSI)
50%
SAMP8
42%
Astrocytes
27%
Adjusted Odds Ratio
25%
Confidence Interval
25%
Learning Impairment
21%
Pt(IV)
20%
Satraplatin
20%
DNA Conformational Change
20%
Reporting Frequency
18%
Big Hole
16%
Tau Phosphorylation
14%
Alzheimer's Disease
14%
Memory Impairment
14%
Oxidative Stress
14%
Auxotrophic Marker
14%
Auxotrophy
14%
VigiBase
12%
Platinum(IV) Complexes
10%
Hydroxyl Radical Scavenging Activity
10%
Radical Scavenging Ability
10%
Neurofibrillary tau Tangles
10%
Tau Tangles
10%
APP Knock-in
10%
DA Receptors
10%
Remote Communication
8%
Expansion Ability
8%
Precise Operation
8%
Operation Field
8%
View Expansion
8%
Socket
8%
Infection-related Mortality
8%
C-reactive Protein Level
8%
Catheter Insertion
8%
